

October 19, 2026

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238 Stock Code: ROSSARI
--	--

Dear Sir/Madam,

Subject.: Q2 & H1 FY27 Press Release

Please find enclosed a copy of the Press Release for the quarter and half year ended September 30, 2026.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,

For Rossari Biotech Limited

Parul Gupta
Digitally signed by Parul Gupta
Date: 2026.10.19 00:20:52 +05'30'



Parul Gupta

Company Secretary & Head - Legal

Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3-24-2 & D3-24-3, Phase III, GIDC Dahej, Village Galenda, Taluka Vagra, Bharuch, Gujarat - 392130, India. T: +91-2641-661621

info@rossari.com

www.rossari.com



Rossari Biotech reports Highest Ever Quarterly Revenue & EBITDA

Mumbai, October 17, 2026: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its unaudited financial results for the quarter and half-year ended September 30, 2026.

Consolidated Q2 FY27 Performance

- Highest-ever quarterly revenue of Rs. 697.6 crores, a 19.0% growth on y-o-y basis
- Highest ever quarterly EBITDA of Rs. 87.0 crores, a 20.9% growth on y-o-y basis
- EBITDA margins stood at 12.5%, up by 20 bps
- Profit After Tax stood at Rs. 38.9 crores, remained subdued due to higher depreciation arising from investments in long-term projects
- Highest-ever export sales of Rs. 216.4 crores, a 33.8% growth on y-o-y basis
- Strong Cash flow from Operations at Rs. 131 crores
- Net working capital improved to 86 days as of September 2026 from 97 days as of March 2026.
- Net debt declined to Rs. 221 crores from Rs. 281 crores as of March 2026

Consolidated H1 FY27 Performance

- Total revenue for the half-year stood at Rs. 1,394.8 crores, a 23.4% growth on y-o-y basis
- EBITDA increased to Rs. 167.6 crores, up 19.9% on y-o-y basis
- EBITDA margins stood at 12.0%, lower by 40 bps
- Profit After Tax stood at Rs. 74.0 crores

Key Business Updates

Kingdom of Saudi Arabia (KSA) Facility

- The Board has approved the leasing of land by Rossari International Limited Company, a wholly owned subsidiary, for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA)

Home, Personal Care and Performance Chemicals

- Successfully completed the Stage 1 EXCiPACT audit for Pharma business
- Strategically expanding our preservative and mild surfactant portfolio
- Agro business in general was sluggish because of El Niño
- Commissioned one of India's largest EO storage facility at our Unitop site

Textile Specialty Chemicals

- New geographies added - Peru and Indonesia
- New products introduced -
 - Yarn and thread lubricants portfolio expanded
 - Spin-finish for Fully Drawn Yarn (FDY)
 - New product category for denim processing

Animal Health and Nutrition

- New range of disinfectants introduced
- Emulsifiers for poultry feed as new product category
- Liquid enzymes for exports
- Biosurfactant based gut health modulator for poultry

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said,

“We delivered robust consolidated growth of 19% YoY in Q2FY27, achieving a record quarterly revenue of Rs. 698 crores. The performance was driven by healthy momentum in the domestic business and the continued expansion of our international presence. We concluded the first half of FY27 on a strong note, with consolidated revenue of Rs. 1,395 crores in H1FY27, a healthy growth of 23% YoY. The growth was broad-based, led by healthy volume, improved product mix and focused execution across our businesses. During Q2FY27, the HPPC, TSC and AHN businesses delivered YoY growth of 18%, 26% and 11%, respectively. Performance was supported by a higher contribution from value-added products and improved wallet share with customers across end-user industries.

We continue to operate under dynamic business environment marked by raw material volatility, geopolitical uncertainty and cautious customer behaviour. Despite of these headwinds in Q2FY27 we maintained the gross margin at ~32% level and EBITDA margin at ~12.5% level.

During H1FY27, we made progress in strengthening our balance sheet and improving cash flow generation. Our net working capital cycle improved to 86 days as of 30 September 2026, compared with 97 days as of 31 March 2026. Further, net debt declined to Rs. 221 crores from Rs. 281 crores over the same period.

We are pleased to announce that the Board has approved the leasing of land to Rossari International Limited Company (RILC), our wholly owned subsidiary, for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). This builds on the in-principle approval granted by the Board earlier and marks a key milestone in Rossari’s international growth journey.

Our strategic initiatives are progressing in the right direction. These include monetising non-core assets, rationalising lower-margin businesses and improving the product mix. We remain confident that operating leverage, scale benefits and these initiatives will support progressive improvement in profitability. With strong R&D capabilities, expanding capacities, a healthy balance sheet and a growing global footprint, we are well placed to build an integrated, intelligent and impactful specialty chemicals platform and deliver sustained long-term growth.”

Note: Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN)

About Rossari Biotech Limited

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For further details please contact:



Rossari Biotech Limited

CIN – L24100MH2009PLC194818

Mr. Ketan Sablok

Email – ketan.sablok@rossari.com

www.rossari.com

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Investor Relations:

Mr. Sudarshan Dhekane – 91 9137013450

Email – sudarshan.dhekane@sgapl.net

Ms. Vaamaa Choksi – 91 9022208577

Email – vaamaa.choksi@sgapl.net

www.sgapl.net

Disclaimer:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.